SEC Filings
Novocure’s Optune Mya Rejected By FDA Over Uncertainty About Its Clinical Benefit
The company plans to ask whether approval is possible without additional clinical studies; the FDA raised no safety concerns.
Novocure (NVCR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The company plans to ask whether approval is possible without additional clinical studies; the FDA raised no safety concerns.
Earnings
CEO Frank Leonard says practices swamped by a rival's launch limit access for Optune Pax, and Novocure plans two small KRAS-inhibitor trials.
Earnings
The company's $736 million to $743 million revenue guide implies a softer fourth quarter than the $193 million just reported.
SEC Filings
The tumor-therapy maker also lifted its adjusted EBITDA outlook to $24 million to $34 million, from $0 million to $15 million.
Earnings
Operating cash flow was a $17.3 million inflow for nine months, while term-loan repayments start in the third quarter of 2027.